Warren C. Stone's most recent trade in Neogenomics Inc. was a trade of 9,613 Restricted Stock Unit done . Disclosure was reported to the exchange on May 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2025 | 9,613 | 9,613 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2025 | 9,613 | 104,921 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 8.58 per share. | 11 May 2025 | 5,700 | 108,280 (0%) | 0% | 8.6 | 48,895 | Common Stock |
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 11 May 2025 | 2,341 | 102,580 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 5,969 | 96,762 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 May 2025 | 1,454 | 95,308 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone C. | Pres & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 94,518 | 94,518 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Warren Stone C. | Pres & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 52,687 | 52,687 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 143,266 | 143,266 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 84,317 | 84,317 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 93,265 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 16,886 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 2,472 | 90,793 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit |